Monday, May 04, 2026 12:46:20 PM
Companies that follow Canadian and US public stock rules and that are engaged in preparation for Chemical and Biological warfare when not long ago Syria was using Chemical weapons in the Middle east, we will have few if any clue ahead of time (IMO) when and if they are closing a massive deal to sell and stockpile an antigen Bucillamine for the US (at war with Iran) or Canada and NATO until the Military lets them, or the financials show huge profits.
The applications for Bucillamine are many and plenty-full. I was right long ago when I suggested it could be used to save lives fighting illegal chemical warfare agents. The issued Patent (one of possibly many world wide) is the proof.
The applications for Bucillamine are many and plenty-full. I was right long ago when I suggested it could be used to save lives fighting illegal chemical warfare agents. The issued Patent (one of possibly many world wide) is the proof.
Bullish
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
